Trial · NCT00702273
Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)
NCT00702273, Completed, Organon and Co; results first posted 2014-11-20
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716). Trials, record NCT00702273. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00702273
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)
- NCT number
- NCT00702273
- Status
- Completed
- Enrollment
- 344 participants, actual
- Lead sponsor
- Organon and Co
- Conditions
- In Vitro Fertilization
- Interventions
150 µg Corifollitropin Alfa, 200 IU RecFSH/Follitropin beta (Days 1 to 7), Placebo for Corifollitropin Alfa, Placebo for RecFSH/Follitropin beta, 200 IU RecFSH/Follitropin beta (Days 8 to hCG), Ganirelix, hCG, Progesterone
- First posted
- 2008-06-20
- Last updated
- 2024-09-05
- Other registries' IDs
- eudract:2004-004773-28
- Results first posted
- 2014-11-20
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With an Ongoing Pregnancy (Cumulative Ongoing Pregnancy Rate) | Up to 1 year after embryo transfer in base trial P05787 (NCT00696800), and FTET cycles in follow up trial | An ongoing pregnancy is the presence of at least one fetus with heart activity at least 10 weeks after embryo transfer or confirmed by live birth.The cumulative ongoing pregnancy rate is 100 times the number of participants with an ongoing pregnancy either immediately after embryo transfer in base Trial P05787 (NCT00696800), or after one or more FTET cycles in follow-up Trial P05716 following cryopreservation, divided by the total number of participants that started treatment in base Trial P05787 (NCT00696800). Participants who did not have cryopreserved embryos, or embryo transfers in the FTET cycle(s), were considered 'not pregnant'. |
| Secondary | Percentage of Participants in Follow up Trial With a Miscarriage Per Clinical Pregnancy | After one or more FTET cycles, up to day of miscarriage (up to 1 year) | Miscarriages were calculated per clinical pregnancy, meaning the presence of at least one gestational sac or confirmed by live birth. |
| Secondary | Percentage of Participants in Follow up Trial With a Miscarriage Per Vital Pregnancy | After one or more FTET cycles, up to day of miscarriage (up to 1 year) | Miscarriages were calculated per vital pregnancy, meaning the presence of at least one fetus with heart activity. |
| Secondary | Percentage of Participants in Follow up Trial With an Ectopic Pregnancy | After one or more FTET cycles, assessed at least 10 weeks after embryo transfer (up to 1 year) | An ectopic pregnancy is where the embryo implants outside the uterus. Ectopic pregnancies were calculated per total number of participants started in FTET. |
| Secondary | Percentage of Participants in Follow up Trial With a Clinical Pregnancy | After one or more FTET cycles, assessed at least 10 weeks after embryo transfer (up to 1 year) | A clinical pregnancy is the presence of at least gestational sac or confirmed by live birth. Clinical pregnancies were calculated per attempt, meaning if any stage of in vitro fertilization (IVF) treatment was not achieved, zero values were imputed. |
| Secondary | Percentage of Participants in Follow up Trial With a Vital Pregnancy | After one or more FTET cycles, assessed at least 10 weeks after embryo transfer (up to 1 year) | A vital pregnancy is the presence of at least one fetus with heart activity. Vital pregnancies were calculated per attempt, meaning if any stage of IVF treatment was not achieved, zero values were imputed. |
| Secondary | Percentage of Participants in Follow up Trial With an Ongoing Pregnancy | After one or more FTET, assessed at least 10 weeks after embryo transfer or at live birth (up to 1 year) | An ongoing pregnancy is the presence of at least one fetus with heart activity at least 10 weeks after embryo transfer or confirmed at live birth. Ongoing pregnancies were calculated per attempt, meaning if any stage of IVF treatment was not achieved, zero values were imputed. |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With an Ongoing Pregnancy (Cumulative Ongoing Pregnancy Rate) | Up to 1 year after embryo transfer in base trial P05787 (NCT00696800), and FTET cycles in follow up trial | ITT group from base trial P05787, consisting of randomized participants who were treated with Corifollitropin Alfa or recFSH. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants in Follow up Trial With a Miscarriage Per Clinical Pregnancy | After one or more FTET cycles, up to day of miscarriage (up to 1 year) | Participants enrolled in P05716 Follow Up study that had a clinical pregnancy. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants in Follow up Trial With a Miscarriage Per Vital Pregnancy | After one or more FTET cycles, up to day of miscarriage (up to 1 year) | Participants enrolled in P05716 Follow Up study that had a vital pregnancy. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants in Follow up Trial With an Ectopic Pregnancy | After one or more FTET cycles, assessed at least 10 weeks after embryo transfer (up to 1 year) | Participants enrolled in P05716 Follow Up study. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants in Follow up Trial With a Clinical Pregnancy | After one or more FTET cycles, assessed at least 10 weeks after embryo transfer (up to 1 year) | Participants enrolled in P05716 Follow Up study, that had an embryo transfer in the respective cycle. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants in Follow up Trial With a Vital Pregnancy | After one or more FTET cycles, assessed at least 10 weeks after embryo transfer (up to 1 year) | Participants enrolled in P05716 Follow Up study, that had an embryo transfer in the respective cycle. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants in Follow up Trial With an Ongoing Pregnancy | After one or more FTET, assessed at least 10 weeks after embryo transfer or at live birth (up to 1 year) | Participants enrolled in P05716 Follow Up study, that had an embryo transfer in the respective cycle. | Percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With an Ongoing Pregnancy (Cumulative Ongoing Pregnancy Rate) | 150 µg Corifollitropin Alfa | 47.2 | Percentage of participants | ||
| Percentage of Participants With an Ongoing Pregnancy (Cumulative Ongoing Pregnancy Rate) | 200 IU RecFSH | 44.9 | Percentage of participants | ||
| Percentage of Participants in Follow up Trial With a Miscarriage Per Clinical Pregnancy | 150 µg Corifollitropin Alfa | 8.2 | Percentage of participants | ||
| Percentage of Participants in Follow up Trial With a Miscarriage Per Clinical Pregnancy | 200 IU RecFSH | 17.6 | Percentage of participants | ||
| Percentage of Participants in Follow up Trial With a Miscarriage Per Vital Pregnancy | 150 µg Corifollitropin Alfa | 0 | Percentage of participants | ||
| Percentage of Participants in Follow up Trial With a Miscarriage Per Vital Pregnancy | 200 IU RecFSH | 0 | Percentage of participants | ||
| Percentage of Participants in Follow up Trial With an Ectopic Pregnancy | 150 µg Corifollitropin Alfa | 1.2 | Percentage of participants | ||
| Percentage of Participants in Follow up Trial With an Ectopic Pregnancy | 200 IU RecFSH | 0.6 | Percentage of participants | ||
| Percentage of Participants in Follow up Trial With a Clinical Pregnancy | 150 µg Corifollitropin Alfa | 43.5 | Percentage of participants | ||
| Percentage of Participants in Follow up Trial With a Clinical Pregnancy | 200 IU RecFSH | 38.6 | Percentage of participants |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 results by groupParticipant flow14
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Base Study P05787 (NCT00696800) | STARTED | 150 µg Corifollitropin Alfa | 757 | |
| Base Study P05787 (NCT00696800) | STARTED | 200 IU RecFSH | 752 | |
| Base Study P05787 (NCT00696800) | Treated | 150 µg Corifollitropin Alfa | 756 | |
| Base Study P05787 (NCT00696800) | Treated | 200 IU RecFSH | 750 | |
| Base Study P05787 (NCT00696800) | COMPLETED | 150 µg Corifollitropin Alfa | 672 | |
| Base Study P05787 (NCT00696800) | COMPLETED | 200 IU RecFSH | 704 | |
| Base Study P05787 (NCT00696800) | NOT COMPLETED | 150 µg Corifollitropin Alfa | 85 | |
| Base Study P05787 (NCT00696800) | NOT COMPLETED | 200 IU RecFSH | 48 | |
| Follow Up Study P05716 (NCT00702273) | STARTED | 150 µg Corifollitropin Alfa | 168 | |
| Follow Up Study P05716 (NCT00702273) | STARTED | 200 IU RecFSH | 176 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 participant flowAdverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Ectopic pregnancy | Pregnancy, puerperium and perinatal conditions | 150 µg Corifollitropin Alfa | 1 | 168 | 1 |
| serious | Ectopic pregnancy | Pregnancy, puerperium and perinatal conditions | 200 IU RecFSH | 0 | 176 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 150 µg Corifollitropin Alfa | ||
| Total, all-cause mortality | 200 IU RecFSH | ||
| Total, other adverse events | 150 µg Corifollitropin Alfa | 0 | 168 |
| Total, other adverse events | 200 IU RecFSH | 0 | 176 |
| Total, serious adverse events | 150 µg Corifollitropin Alfa | 1 | 168 |
| Total, serious adverse events | 200 IU RecFSH | 0 | 176 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22459628 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| 150 µg Corifollitropin Alfa vs 200 IU RecFSH: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00702273
GET https://conductscience.org/api/trials/v1/NCT00702273/registered